Trial
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Pediatric Cancer (Oncology)
Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Age: >1 and <31 years of age at the time of study enrollment
Pre-B ALL in first early (<36 months from diagnosis) isolated bone marrow or combined bone marrow/extramedullary relapse; OR T-cell ALL in first isolated bone marrow or combined relapse; OR T-LL in first relapse
Patients with leukemia must have had histologic verification of the malignancy at relapse, including immunophenotyping to confirm diagnosis
Patients with lymphoblastic lymphoma must have measurable disease documented by clinical, radiographic, or histologic criteria
Patients must have relapsed or become refractory to conventional therapy
Patients who relapse while received standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study
Patients who relapse on therapy other than standard ALL maintenance therapy must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
Adequate kidney, liver, heart, and lung functions
Principal Investigator Name
Janice Olson, MD
Children's Cancer and Blood Disorders Program
Last Updated:
Wednesday, January 27, 2021 11:41:04 AM